NVL-655 is designed to remain active in tumors that have developed resistance to first-, second-, and third-generation ALK inhibitors, including tumors with the solvent front G1202R mutation or ...

NVL-655 is currently being evaluated in the ALKOVE-1 Phase 1/2 clinical trial, a first-in-human study of NVL-655 in patients with advanced ALK-positive NSCLC and other solid tumors (NCT05384626).

NVL-520 is currently being investigated in the ARROS-1 study, a first-in-human Phase 1/2 clinical trial for patients with advanced non-small cell lung cancer (NSCLC) and other solid tumors.

Nvidia (NASDAQ:NVDA) is likely to offer up “strong” results and guidance when it reports quarterly results next week, despite the GB200 NVL constraints it has faced, KeyBanc Capital Markets ...

Details of the poster presentations are as follows: Title: Preclinical characterization of NVL-330, a selective and brain penetrant HER2 tyrosine kinase inhibitor with broad activity on HER2 ...

The NVL-520 oral presentation represents the first report of preliminary safety and clinical activity data from the dose-escalation portion of the company's ongoing Phase 1/2 ARROS-1 study ...

The NVL-520 oral presentation represents the first report of preliminary safety and clinical activity data from the dose-escalation portion of the company's ongoing Phase 1/2 ARROS-1 study ...